ID3-directed sonogenetics to enhance osteogenesis and bone defect healing Authors: Huan Liu, Yifan Xu, Xue Wang, Meijing Liu, Jinsong Wang, Sijia Na, Xiaogang Wang, Songlin Wang, Lei Hu Published: 2026 ABSTRACT Sonogenetics, a noninvasive approach combining ultrasound physics with genetic engineering, has shown clinical potential in promoting bone repair. However, its therapeutic efficacy remains suboptimal due to the scarcity of bone-specific ultrasound-responsive targets and insufficient modulation of osteogenic signaling pathways. Herein, we investigated the role of the transcriptional repressor inhibitor of DNA binding/differentiation 3 (Id3) in bridging sonogenetics and bone regeneration. RNA sequencing and PCR array analyses revealed significant downregulation of Id3 during low-intensity pulsed ultrasound (LIPUS)-induced bone formation, suggesting Id3 acts as a “brake” on ultrasound-mediated osteogenesis. As a member of the ID protein family, Id3 binds to basic helix-loop-helix (bHLH) transcription factors (e.g., E-proteins) to suppress their DNA-binding capacity and osteogenic gene transcription-particularly in bone marrow-derived mesenchymal stem cells (BMSCs), a key cell type for bone repair. Functional experiments demonstrated that Id3 knockdown enhanced LIPUS-induced osteogenic differentiation of BMSCs in vitro (upregulating RUNX2, OCN) and promoted in vivo bone formation in rodent bone defect models, while Id3 overexpression reversed these effects. Chromatin immunoprecipitation (ChIP) assays confirmed that Id3 directly targets bHLH proteins to inhibit the Bmp/Smad pathway, a core cascade for osteogenesis. Based on these findings, we propose an ID3-based sonogenetic strategy: we engineered an Id3-inhibitory peptide (rID3) targeting the Id3/E2A interface, which would synergize with LIPUS to enhance defect healing of cranial bone. Our work delineates a novel CaN/NFATC3/Id3/E2A/Bmp4 pathway for ultrasound mechanobiology and provides a promising combinatorial therapeutic strategy for precision sonogenetics bone regeneration. Introduction In the field of regenerative medicine, tissue repair disorders such as nonunion fractures,1 chronic refractory wounds,2 and nerve injuries3 remain formidable challenges in clinical treatment. Bone defect repair, a critical focus in regenerative medicine, remains a formidable clinical challenge-particularly in cases of nonunion fractures, large segmental defects, and osteoporotic fractures.4 Globally, millions of patients suffer from impaired bone healing annually, with conventional treatments (e.g., autologous bone grafts, synthetic scaffolds) yielding limited efficacy: autologous grafts face donor scarcity and donor-site morbidity, while synthetic scaffolds often lack osteogenic specificity and poor integration with host bone.5 These approaches not only fail to address the spatiotemporal precision required for bone regeneration but also carry invasive risks (e.g., surgical implantation) that prolong patient recovery.6,7 The unmet need for non-invasive, bone-specific regenerative strategies has driven interest in emerging technologies. Sonogenetics, an emerging non-invasive technology integrating ultrasound physics and genetic engineering, achieves remote, spatiotemporally precise regulation of target cells via ultrasound-sensitive proteins that respond to ultrasound’s mechanical (acoustic radiation force, cavitation) or thermal effects.8,9 This technology avoids surgical invasiveness (e.g., compared to implantable electrodes) and systemic drug side effects, showing promise in tissue regeneration.10,11 However, its application in bone defect repair remains limited due to a lack of a bone-specific sonogenetic regulatory system, creating a critical research gap, emphasizing the need to identify bone-enriched ultrasound-sensitive molecules and couple sonogenetics with osteogenic pathways for clinical translation. Ultrasound exerts its mechanobiological effects partly through mechanosensitive ion channels and calcium signaling.12,13 However, the specific molecular sensors, the immediate downstream effectors, and the comprehensive pathways linking the initial mechanotransduction event to the activation of pro-regenerative genetic programs, such as the bone morphogenetic protein (BMP) pathway essential for bone formation, are poorly defined.14,15 Transcription regulators, including transcription activators (“on” switches) and repressors (“off” switches), are essential regulators of cellular adaptation and response to physical field stimuli, which function as sensing, responding, and transducing.16 In the field of ultrasound therapy, many transcription activators have been reported to be activated in response to ultrasound stimulation, thereby promoting cell proliferation, differentiation, and tissue repair.17–21 However, transcriptional repressors, another kind of transcriptional regulator, have rarely been investigated. In this study, RNA sequencing (RNA-seq) analysis revealed that multiple transcriptional repressors, including inhibitors of DNA binding/differentiation (ID) proteins, were significantly downregulated during the early phase of low-intensity pulsed ultrasound (LIPUS)-induced bone formation. This suggests that specific transcriptional repressors may exert a “braking effect” on LIPUS-mediated osteogenesis. ID proteins represent a crucial class of transcriptional repressors whose members bind to E-box (CANNTG) sequences in target gene promoter regions. By doing so, they inhibit the activity of DNA-binding proteins (such as basic helix-loop-helix (bHLH) transcription factors), thereby regulating cellular processes. Our preliminary RNA-seq and polymerase chain reaction (PCR) array analyses revealed that inhibitor of DNA binding/differentiation 3 (Id3), a transcriptional repressor in the ID protein family, is significantly downregulated during LIPUS-induced bone formation. As a member of the ID family, Id3 binds to bHLH transcription factors (e.g., E-proteins), inhibiting their dimerization and DNA-binding capacity—thereby suppressing transcriptional activity of osteogenic genes.22 Id3 is highly expressed in bone marrow-derived mesenchymal stem cells (BMSCs), a key cell type for bone regeneration, and its downregulation correlates with enhanced osteoblast differentiation.22 These findings suggest that Id3 may act as a bone-specific “brake” on ultrasound-mediated osteogenesis: targeting Id3 could sensitize BMSCs to ultrasound stimulation, addressing the current lack of bone-specificity in sonogenetics. In this study, we aim to develop an ID3-based sonogenetic system for promoting bone defect repair. Specifically, we validate the role of Id3 in LIPUS-induced osteogenesis by investigating the effects of Id3 knockdown and overexpression on BMSCs osteogenic capabilities (in vitro) and in vivo bone formation in rodent bone defect models. Then, we elucidate the molecular mechanism of Id3 via chromatin immunoprecipitation (ChIP) assays, focusing on its interaction with bHLH proteins and regulation of Bmp/Smad/Wnt pathways-core osteogenic cascades. At last, we generate an ID3-targeted sonogenetic strategy: couple ultrasound-sensitive peptides to target Id3 regulatory elements to achieve bone-specific activation of osteogenic programs under LIPUS. Results Screening of key transcriptional repressors for LIPUS-induced bone formation The gene expression profiles of mouse tibia tissues stimulated by LIPUS (30 mW/cm2) were analyzed by RNA-seq, and a large number of transcriptional repressors were down-regulated in the differential expression results, suggesting the existence of a “braking” mechanism (Supplementary Fig. 1a–d). To screen for key transcriptional repressors in response to ultrasound, we designed customized PCR arrays containing 44 common transcriptional repressors based on sequencing results (Fig. 1a). Heatmaps show the differentially expressed genes in the array results (Fig. 1b). Genes were significantly up-or down-regulated (P < 0.05) if the average fold change in expression was 2.0 or 0.5 compared with controls. Of the 44 genes tested, 16 had changes in mRNA levels: 2 were upregulated, and 14 were downregulated. Among the differentially down-regulated genes, more than 3-fold fold change was observed for Aebp1, Id3, Thap7, and Mdfi (Fig. 1c). We subsequently analyzed the correlation of these four genes with bone or osteogenesis by bibliometrics in which Id3 retrieved significantly more literature than the other three genes (Fig. 1d), and these were enriched for topics such as osteogenic differentiation, bone morphogenetic proteins, and growth factor β (Fig. 1e), which suggests that Id3 may be associated with LIPUS-induced bone responses. To further confirm the accuracy of the differential genes, we performed real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) validation, which showed that the trends of the differential genes were consistent with the array results. Among them, Id3 was significantly down-regulated with a large differential fold and small intra-group differences (Fig. 1f, Supplementary Fig. 2a). Meanwhile, this result was validated at the cellular level, where only Id3 gene expression was downregulated in human bone marrow mesenchymal stem cells (hBMSCs) and mouse bone marrow mesenchymal stem cells (mBMSCs) after LIPUS stimulation (Fig. 1g, h), but there was no difference in Mdfi, Aebp1 and Thap7 genes (Supplementary Fig. 2b, c). These results suggest that Id3 may be a key response molecule for ultrasound-induced bone effects.Fig. 1Screening of key transcriptional repressors for LIPUS-induced bone formation. a Schematic diagram: customized PCR arrays screen for key transcriptional repressors in LIPUS-induced bone formation (n = 4). (Created with BioRender.com). b Heat map: PCR array results of 44 transcriptional repressors of LIPUS vs. Control (n = 4). c Volcano plot: differentially expressed genes of LIPUS vs. Control, genes with P < 0.05 & |FoldChange|> 3 are labeled (n = 4). d Quantitative plot: number of documents related to the search terms bone* or osteo* with four genes: Id3, Aebp1, Thap7, and Mdfi. e Enrichment plot: the keywords enriched in Id3’s bone-related literature. f RT-qPCR: validation of mRNA levels of Id3, Aebp1, Thap7, and Mdfi genes in PCR array results using LIPUS-stimulated bone tissue (n = 4). g RT-qPCR: Id3 mRNA levels after LIPUS stimulation of mBMSCs (n = 3). h RT-qPCR: ID3 mRNA levels after LIPUS stimulation of hBMSCs (n = 3). Values are means ± standard deviation (SD); *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (t-test for f, g, and h) Screening of key transcriptional repressors for LIPUS-induced bone formation. a Schematic diagram: customized PCR arrays screen for key transcriptional repressors in LIPUS-induced bone formation (n = 4). (Created with BioRender.com). b Heat map: PCR array results of 44 transcriptional repressors of LIPUS vs. Control (n = 4). c Volcano plot: differentially expressed genes of LIPUS vs. Control, genes with P < 0.05 & |FoldChange|> 3 are labeled (n = 4). d Quantitative plot: number of documents related to the search terms bone* or osteo* with four genes: Id3, Aebp1, Thap7, and Mdfi. e Enrichment plot: the keywords enriched in Id3’s bone-related literature. f RT-qPCR: validation of mRNA levels of Id3, Aebp1, Thap7, and Mdfi genes in PCR array results using LIPUS-stimulated bone tissue (n = 4). g RT-qPCR: Id3 mRNA levels after LIPUS stimulation of mBMSCs (n = 3). h RT-qPCR: ID3 mRNA levels after LIPUS stimulation of hBMSCs (n = 3). Values are means ± standard deviation (SD); *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (t-test for f, g, and h) Id3 deficiency enhances osteogenic differentiation and bone formation Next, the bone-related phenotype of Id3 in vivo was studied. The Id3 knockout (KO) mice model was constructed (Identification results of mouse tail in Supplementary Fig. 3a). To assess the role of Id3 in osteogenic differentiation, long bone marrow-derived mesenchymal stem cells (BMMSCs) from Id3 KO mice and wild-type (WT) mice were isolated and cultured (Fig. 2a, Supplementary Fig. 3b). Positive Ki67 staining showed that Id3 KO BMMSCs’ proliferative activity was significantly higher than WT BMMSCs (Fig. 2b, c). On day 7 of differentiation in the osteogenic induction medium, alkaline phosphatase (ALP) activity was significantly higher in Id3 KO BMMSCs (Fig. 2d, f), and calcium mineralization was enhanced considerably in Id3 KO BMMSCs on day 21, as shown by alizarin red staining (ARS) (Fig. 2e, g). Meanwhile, increased Alp expression in Id3 KO BMMSCs was observed on days 1, 3, 7, and 14 of osteogenic induction (Fig. 2h). Illustrative micro-computed tomography (CT) images of the femurs were displayed to demonstrate skeletal changes (Fig. 2i). For trabecular bone, Id3 KO mice had higher bone mass, verified by higher bone volume/tissue volume (BV/TV), trabecular thickness (Tb. Th), trabecular number (Tb. N), and bone mineral density (BMD) (Fig. 2j–m), as well as lower bone surface/bone volume (BS/BV) ratio, and trabecular bone pattern factor (Tb. pf) (Fig. 2n, o). These results indicated that Id3 deficiency enhances osteogenic differentiation and bone formation. For further validation, we constructed a recombinant adeno-associated virus (AAV) (rAAV9.DSS-Nter-Id3) with bone-targeting ability and specifically overexpressed Id3 in bone tissues. The results showed that Id3 overexpression resulted in a significant decrease in BV/TV, Tb. Th, Tb. N, and BMD, and a substantial increase in the structural modeling index (SMI) and Tb. pf, suggesting bone formation was inhibited (Supplementary Fig. 3c–i). In conclusion, Id3 is a key negative regulator of bone formation.Fig. 2Id3 deficiency enhances osteogenic differentiation and bone formation. a Schematic diagram: isolation and culture of Id3 KO mice BMMSCs. (Created with BioRender.com). b Ki67 staining: proliferative activity of KO BMMSCs and WT BMMSCs (n = 3). c Quantitative analysis: percentage of Ki67+ cell number in KO BMMSCs and WT BMMSCs (n = 3). d ALP staining: KO BMMSCs and WT BMMSCs osteogenic induction for seven days (n = 3). e Alizarin red staining: KO BMMSCs and WT BMMSCs osteogenic induction for 21 days (n = 3). f Quantification analysis: ALP activity in KO BMMSCs and WT BMMSCs at seven days of osteogenic induction (n = 3). g Quantitative analysis: the absorbance of alizarin red was detected after 21 days of osteogenic induction of KO BMMSCs and WT BMMSCs, and the detection wavelength was 562 nm (n = 3). h RT-qPCR: Alp mRNA levels of KO BMMSCs and WT BMMSCs on the 1st, 3rd, 7th, and 14th day after osteogenesis (n = 3). i CT reconstructed images: femoral trabecular structures in 12-month-old KO mice and 12-month-old WT mice (n = 4). j–o Quantitative analysis: femoral BV/TV, Tb. Th, Tb. N, BMD, BS/BV, Tb. pf in 12-month-old KO mice and 12-month-old WT mice (n = 4). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (t-test for c, f, g, h, and j–o) Id3 deficiency enhances osteogenic differentiation and bone formation. a Schematic diagram: isolation and culture of Id3 KO mice BMMSCs. (Created with BioRender.com). b Ki67 staining: proliferative activity of KO BMMSCs and WT BMMSCs (n = 3). c Quantitative analysis: percentage of Ki67+ cell number in KO BMMSCs and WT BMMSCs (n = 3). d ALP staining: KO BMMSCs and WT BMMSCs osteogenic induction for seven days (n = 3). e Alizarin red staining: KO BMMSCs and WT BMMSCs osteogenic induction for 21 days (n = 3). f Quantification analysis: ALP activity in KO BMMSCs and WT BMMSCs at seven days of osteogenic induction (n = 3). g Quantitative analysis: the absorbance of alizarin red was detected after 21 days of osteogenic induction of KO BMMSCs and WT BMMSCs, and the detection wavelength was 562 nm (n = 3). h RT-qPCR: Alp mRNA levels of KO BMMSCs and WT BMMSCs on the 1st, 3rd, 7th, and 14th day after osteogenesis (n = 3). i CT reconstructed images: femoral trabecular structures in 12-month-old KO mice and 12-month-old WT mice (n = 4). j–o Quantitative analysis: femoral BV/TV, Tb. Th, Tb. N, BMD, BS/BV, Tb. pf in 12-month-old KO mice and 12-month-old WT mice (n = 4). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (t-test for c, f, g, h, and j–o) Id3 inhibits LIPUS-induced osteogenesis of BMSCs We found that Id3 was significantly reduced in ultrasound-induced osteogenesis and that Id3 deficiency enhanced in vitro osteogenesis in BMSCs. This suggests that Id3 is likely to be a key negative regulator of ultrasound-induced osteogenesis. To further clarify the biological role of Id3 in LIPUS-induced osteogenic differentiation, we overexpressed Id3 in the ultrasound-induced osteogenic differentiation system of mBMSCs. RT-qPCR verified that the level of Id3 was significantly elevated (Supplementary Fig. 4a). Id3 overexpression (OE) significantly suppressed cell viability and osteogenic differentiation of mBMSCs, which directly supported a negative regulatory role for Id3 in osteogenesis (Supplementary Fig. 4b–d). Next, we performed functional validation (Fig. 3a). First, Edu and Tunel staining suggested that LIPUS treatment could promote the proliferation of mBMSCs and inhibit the apoptosis of mBMSCs. Meanwhile, OE-Id3 mBMSCs followed by LIPUS treatment again showed no significant change in cell activity (Fig. 3b, c, Supplementary Fig. 4e). Similarly, the intensity of ALP staining on the 7th day and ARS staining on the 21st day of mBMSCs osteogenesis induction was significantly enhanced after LIPUS treatment. However, in OE-Id3 mBMSCs, LIPUS-induced osteogenic differentiation disappeared (Fig. 3d). This observation was confirmed by quantitative analysis of ALP activity and calcium mineralization (Fig. 3e, f). The expression of a range of osteogenic marker genes also demonstrated the inhibitory effect of Id3. After LIPUS treatment, Alp, Runx2, Col1, Ocn, Osx, and Opn were significantly upregulated, offset by overexpression of Id3 (Fig. 3g–l). Consistently, we observed the same phenomena in human BMSCs (Supplementary Fig. 5). Further loss-of-function experiments showed that Id3 knockdown combined with LIPUS stimulation significantly promoted BMSCs proliferation, reduced apoptosis, and enhanced osteogenic differentiation. Together with the previous Id3 overexpression results, these data confirm that Id3 is a key negative regulator inhibiting LIPUS-induced osteogenesis of BMSCs (Supplementary Figs. 6, 7).Fig. 3Id3 inhibits LIPUS-induced osteogenesis of mBMSCs. a Schematic diagram: in vitro exploration of the role of Id3 in LIPUS-induced osteogenesis in mBMSCs. The experimental groups are Control, Vector, Vector+LIPUS, and Id3+LIPUS. (Created with BioRender.com). b Edu staining: proliferative activity of mBMSCs in four groups: Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). c Quantitative analysis: the percentage of Edu+ cell number of mBMSCs in the four groups of Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). d ALP staining (top) and alizarin red staining (bottom): Control, Vector, Vector+LIPUS, Id3+LIPUS four groups of mBMSCs cultured in osteogenic medium for seven days (top) and osteogenic medium for 21 days (bottom) (n = 3). e Quantitative analysis: ALP activity on day 7 of osteogenic induction of mBMSCs in the four Control, Vector, Vector+LIPUS, and Id3+LIPUS groups (n = 3). f Quantitative analysis: alizarin red absorbance assay on day 21 of osteogenic induction of mBMSCs in the four groups of Control, Vector, Vector+LIPUS, and Id3+LIPUS. The detection wavelength was 562 nm (n = 3). g-l RT-qPCR: Alp, Runx2, Col1, Ocn, Osx, and Opn mRNA levels on day 7 of osteogenic induction of mBMSCs in four groups: Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way analysis of variance (ANOVA) for c, and e–l) Id3 inhibits LIPUS-induced osteogenesis of mBMSCs. a Schematic diagram: in vitro exploration of the role of Id3 in LIPUS-induced osteogenesis in mBMSCs. The experimental groups are Control, Vector, Vector+LIPUS, and Id3+LIPUS. (Created with BioRender.com). b Edu staining: proliferative activity of mBMSCs in four groups: Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). c Quantitative analysis: the percentage of Edu+ cell number of mBMSCs in the four groups of Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). d ALP staining (top) and alizarin red staining (bottom): Control, Vector, Vector+LIPUS, Id3+LIPUS four groups of mBMSCs cultured in osteogenic medium for seven days (top) and osteogenic medium for 21 days (bottom) (n = 3). e Quantitative analysis: ALP activity on day 7 of osteogenic induction of mBMSCs in the four Control, Vector, Vector+LIPUS, and Id3+LIPUS groups (n = 3). f Quantitative analysis: alizarin red absorbance assay on day 21 of osteogenic induction of mBMSCs in the four groups of Control, Vector, Vector+LIPUS, and Id3+LIPUS. The detection wavelength was 562 nm (n = 3). g-l RT-qPCR: Alp, Runx2, Col1, Ocn, Osx, and Opn mRNA levels on day 7 of osteogenic induction of mBMSCs in four groups: Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way analysis of variance (ANOVA) for c, and e–l) Id3 dampens LIPUS-induced bone formation in vivo To confirm the direct role of Id3 in inhibiting LIPUS-induced bone formation in vivo, we constructed rAAV9.DSS-Nter-Id3 with bone targeting ability to overexpress Id3 in bone tissue in vivo. The results showed that the expression of the Id3 gene in the long bones of mice injected with rAAV9.DSS-Nter-Id3 was significantly increased, while the bone formation ability was weakened (Supplementary Fig. 8a-h). Subsequently, the mice were stimulated by LIPUS for two weeks (Fig. 4a). 3D Micro-CT reconstructed images showed that the tibial bone mass of mice treated with LIPUS increased significantly. After intervention with rAAV9.DSS-Nter-Id3, the bone mass gain of LIPUS-induced disappeared (Fig. 4b). The quantitative analysis of bone parameters showed an increase in BV/TV, Tb. Th, Tb. N, BMD, and a decrease in BS/BV and Tb. pf in the LIPUS group compared to the control group. Intervention with rAAV9.DSS-Nter-Id3 reversed these changes (Fig. 4c-h). In addition, calcein/xylenol orange was used to mark the calcium deposition lines before and after ultrasound to characterize the new bone mass. The results showed a significant increase in bone formation in LIPUS-treated mice compared with control mice. However, overexpression of Id3 deterred the LIPUS-induced increase in bone formation (Fig. 4i). In addition, RT-qPCR results showed a significant increase in Alp, Runx2, Col1, Ocn, and Osx expression in LIPUS-treated mice. In contrast, no changes in these osteogenic marker genes were observed in rAAV9.DSS-Nter-Id3 mice treated with LIPUS (Fig. 4j–n). TRAP staining of histological sections showed no significant differences in osteoclast activity among all groups, suggesting that LIPUS regulated bone formation mainly by modulating osteogenic activity instead of osteoclast-mediated bone resorption (Supplementary Fig. 8i, j). A mouse calvarial defect model was constructed, and bone-targeting AAV9 was applied to knock down Id3 expression in calvaria to further explore the role of Id3 in LIPUS-mediated bone formation in vivo. Single Id3 knockdown mildly facilitated calvarial defect healing, and the combination of Id3 knockdown and LIPUS treatment achieved the most favorable bone repair effect (Supplementary Fig. 8k, l). These in vitro and in vivo results collectively prove that Id3 serves as a negative regulator of LIPUS-induced bone formation and obviously suppresses its osteogenic effects. We further verified the targeting ability and biosafety of rAAV9.DSS vector. Tissue fluorescence imaging confirmed its specific targeting to bone tissue with only faint fluorescence signal in the liver (Supplementary Fig. 9), and H&E staining of major organs revealed no systemic cytotoxicity after rAAV9.DSS administration (Supplementary Fig. 10).Fig. 4Id3 dampens LIPUS-induced bone formation in vivo. a Schematic of in vivo experiments: bone-targeted rAAV9.DSS-Nter-Id3 overexpresses Id3 in bone tissue, and LIPUS intervention was initiated after the onset of the effect (RT-qPCR verification, n = 3). The experimental groups were Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5) (Created with BioRender.com). b (Left, center) CT reconstruction images: tibial trabecular structure of Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS mice in the four groups; (Right) Calcium xanthophyll-dimethylphenol orange double-labeling assay: assessment of Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS new bone formation in four groups of mice (n = 5). c–h Quantitative analysis: BV/TV, Tb. Th, Tb. N, BMD, BS/BV, Tb. pf of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS (n = 5). i Quantitative analysis: The distance between two fluorescent lines was the amount of bone formation between two injections (n = 5). j–n RT-qPCR: Alp, Runx2, Col1, Ocn, and Osx mRNA levels in the tibiae of four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS (n = 5). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P <0.000 1; ns, no significance. (t-test for (a); one-way ANOVA for (a, and c–n)) Id3 dampens LIPUS-induced bone formation in vivo. a Schematic of in vivo experiments: bone-targeted rAAV9.DSS-Nter-Id3 overexpresses Id3 in bone tissue, and LIPUS intervention was initiated after the onset of the effect (RT-qPCR verification, n = 3). The experimental groups were Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5) (Created with BioRender.com). b (Left, center) CT reconstruction images: tibial trabecular structure of Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS mice in the four groups; (Right) Calcium xanthophyll-dimethylphenol orange double-labeling assay: assessment of Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS new bone formation in four groups of mice (n = 5). c–h Quantitative analysis: BV/TV, Tb. Th, Tb. N, BMD, BS/BV, Tb. pf of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS (n = 5). i Quantitative analysis: The distance between two fluorescent lines was the amount of bone formation between two injections (n = 5). j–n RT-qPCR: Alp, Runx2, Col1, Ocn, and Osx mRNA levels in the tibiae of four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, AAV9-Id3+LIPUS (n = 5). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P <0.000 1; ns, no significance. (t-test for (a); one-way ANOVA for (a, and c–n)) LIPUS downregulates Id3 and enhances Bmp4-p-Smad1/5-Runx2 signaling Next, we explored the mechanism of how Id3 inhibits LIPUS-induced bone formation. In pathway enrichment by RNA-seq, we found that LIPUS stimulation significantly upregulated Bmp-related pathways (Fig. 5a). Subsequently, we performed RT-qPCR on the Bmp family of factors, including Bmp2, 4, 6, 7, and 9, and showed that Bmp4 was significantly upregulated after ultrasound stimulation (Fig. 5b). Subsequently, it was verified that at the cellular level, Bmp4 was increased considerably after LIPUS stimulation and promoted osteoblast differentiation by activating downstream Smad1/5 phosphorylation and regulating the transcriptional translation of Bmp4 target genes Runx2 and Osx. In contrast, overexpression of Id3 blocked LIPUS-induced activation of Bmp4-related pathways. This phenomenon was consistent with the results in the in vitro experiments of mBMSCs (Fig. 5c, d) and hBMSCs (Fig. 5e, f). In addition, DMH-1 is a specific BMP receptor inhibitor that can be used to block the BMP/SMAD pathway.23 To confirm the role of BMP/SMAD pathway in LIPUS-induced osteogenic differentiation, we treated BMSCs with DMH-1 and examined its effect on BMSCs. The results showed that DMH-1 completely blocked the activation of the LIPUS induced BMSCs related Bmp4-pSmad1/5 pathway restoring Runx2 and Osx to baseline levels (Fig. 5g–j). Furthermore, Id3 is known to regulate target genes by inhibiting E2A formation of heterodimers.22,24–27 In mBMSCs, E2A was reported to bind to the promoter of Bmp4 to regulate Bmp4 transcription and translation22,28,29 (Supplementary Fig. 11a). We validated our results using a ChIP assay, which showed that LIPUS stimulation enhanced the binding of E2A to the Bmp4 promoter in mBMSCs and hBMSCs, which was counteracted by overexpression of Id3 (Supplementary Fig. 11b, c). Moreover, immunofluorescence of bone tissue in vivo showed that Bmp4 expression was significantly upregulated, and downstream p-Smad1/5-Runx2-Osx was activated after LIPUS treatment. In the rAAV9.DSS-Nter-Id3 group, the expression of Bmp4, p-Smad1/5, Runx2, and Osx were significantly suppressed in the bone tissues, even when stimulated by LIPUS (Fig. 6). In conclusion, these data show that LIPUS treatment downregulated Id3 and enhanced the Bmp4-p-Smad1/5-Runx2 signaling in BMSCs, enhancing bone formation.Fig. 5Mechanism of Id3 negatively regulating LIPUS-induced bone formation. a GO enrichment analysis: RNA-seq results of LIPUS vs. Control. b RT-qPCR: Bmp2, Bmp4, Bmp6, Bmp7, and Bmp9 mRNA levels in the tibiae of two groups of mice: Control, LIPUS (n = 4). c, d Western blot of Bmp4, t-Smad1/5, p-Smad1/5, Runx2, Osx, and Gapdh levels in four groups: Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). e, f Western blot of BMP4, t-SMAD1/5, p-SMAD1/5, RUNX2, OSX, and GAPDH levels in four groups: Control, Vector, Vector+LIPUS, ID3+LIPUS (n = 3). g, h Western blot of Bmp4, t-Smad1/5, p-Smad1/5, Runx2, Osx, and Gapdh levels in four groups: Control, LIPUS, DMH-1, DMH-1+LIPUS (n = 3). i, j Western blot of BMP4, t-SMAD1/5, p-SMAD1/5, RUNX2, OSX, and GAPDH levels in four groups: Control, LIPUS, DMH-1, DMH-1+LIPUS (n = 3). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.000 1, ****P < 0.0001; ns, no significance. (t-test for (b); one-way ANOVA for (d, f, h, and j))Fig. 6LIPUS enhances the signal transduction of Bmp4-Smad1/5-Runx2 by downregulating Id3. a Immunofluorescence: Bmp4 staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). b Immunofluorescence: p-Smad1/5 staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). c Immunofluorescence: Runx2 staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). d Immunofluorescence: Osx staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). e–h Quantitative analysis: Fluorescence intensity of Bmp4, p-Smad1/5, Runx2, and Osx proteins in the tibia of four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way ANOVA for e–h) Mechanism of Id3 negatively regulating LIPUS-induced bone formation. a GO enrichment analysis: RNA-seq results of LIPUS vs. Control. b RT-qPCR: Bmp2, Bmp4, Bmp6, Bmp7, and Bmp9 mRNA levels in the tibiae of two groups of mice: Control, LIPUS (n = 4). c, d Western blot of Bmp4, t-Smad1/5, p-Smad1/5, Runx2, Osx, and Gapdh levels in four groups: Control, Vector, Vector+LIPUS, Id3+LIPUS (n = 3). e, f Western blot of BMP4, t-SMAD1/5, p-SMAD1/5, RUNX2, OSX, and GAPDH levels in four groups: Control, Vector, Vector+LIPUS, ID3+LIPUS (n = 3). g, h Western blot of Bmp4, t-Smad1/5, p-Smad1/5, Runx2, Osx, and Gapdh levels in four groups: Control, LIPUS, DMH-1, DMH-1+LIPUS (n = 3). i, j Western blot of BMP4, t-SMAD1/5, p-SMAD1/5, RUNX2, OSX, and GAPDH levels in four groups: Control, LIPUS, DMH-1, DMH-1+LIPUS (n = 3). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.000 1, ****P < 0.0001; ns, no significance. (t-test for (b); one-way ANOVA for (d, f, h, and j)) LIPUS enhances the signal transduction of Bmp4-Smad1/5-Runx2 by downregulating Id3. a Immunofluorescence: Bmp4 staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). b Immunofluorescence: p-Smad1/5 staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). c Immunofluorescence: Runx2 staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). d Immunofluorescence: Osx staining images of the tibia in four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). e–h Quantitative analysis: Fluorescence intensity of Bmp4, p-Smad1/5, Runx2, and Osx proteins in the tibia of four groups of mice: Control, AAV9-NC, AAV9-NC+LIPUS, and AAV9-Id3+LIPUS (n = 5). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way ANOVA for e–h) LIPUS downregulates Id3 expression through the Ca²⁺/Calcineurin/NFATC3 signaling axis After clarifying the downstream pathway of Id3, we further explored the upstream regulatory mechanism of Id3. We found that LIPUS inhibits Id3 expression by activating the Ca²⁺/calcineurin (CaN)/NFATC3 signaling pathway (Fig. 7a). RNA-seq pathway enrichment analysis showed that LIPUS intervention significantly activated the pathway related to calcium inward flow, which was consistent with previous reports (Fig. 7b). In addition, KnockTF 2.0 database analysis revealed that the transcription factor NFATC3, a member of the NFAT family of classical signaling pathways downstream of calcium ions, significantly suppressed Id3 expression (Fig. 7c). Therefore, we focused on the CaN/NFAT signaling axis, a classical downstream pathway of calcium signaling, to elucidate the mechanism by which LIPUS downregulates Id3. Our data showed that cytoplasmic calcium ion concentration was elevated (Fig. 7d–g) and CaN activity was enhanced after LIPUS stimulation (Fig. 7h, i). Simultaneous immunofluorescence and nuclear protein Western blot showed that LIPUS induced nuclear translocation of NFATC3 (Fig. 7j–p). Subsequently, ChIP assay confirmed that the nuclear translocated NFATC3 could directly bind to the Id3 promoter and inhibit its transcription (Supplementary Fig. 11d). These results suggest that LIPUS down-regulates Id3 expression through the Ca²⁺/CaN/NFATC3 signaling axis. To verify the necessity of this signaling axis in LIPUS-stimulated transduction, we performed specific blockade using the mechanosensitive channel blocker Gsmtx4, the CaN inhibitor CsA, and the NFAT inhibitor VIVIT peptide.30 The results showed that Gsmtx4 reduced intracellular calcium concentration but was hardly affected by CsA and VIVIT peptide (Fig. 8a–d). LIPUS-induced CaN activity was blocked by Gsmtx4 and CsA (independent of VIVIT) (Fig. 8e, f). LIPUS-induced nuclear translocation of NFATC3 (Fig. 8g–k, Supplementary Fig. 11e, f), binding of NFATC3 to the Id3 promoter and inhibition of its transcription (Supplementary Fig. 11g–j) were blocked by all three inhibitors. To further confirm the critical role of NFATC3 in LIPUS-induced Id3 downregulation, we performed an in vitro knockdown experiment targeting NFATC3. The results showed that NFATC3 knockdown completely abolished the downregulation of Id3 by LIPUS (Supplementary Fig. 11k, l). Taken together, the data confirm that LIPUS inhibits Id3 expression by activating the Ca²⁺/CaN/NFATC3 signaling pathway.Fig. 7LIPUS inhibit Id3 by target NFATC3. a Pattern Diagram: LIPUS inhibits Id3 expression by activating the Ca²⁺/CaN/NFATC3 signaling pathway (Created with BioRender.com). b RNA-seq pathway enrichment analysis showed that LIPUS intervention significantly activated the pathway related to calcium inward flow. c KnockTF 2.0 database analysis revealed that the transcription factor NFATC3 significantly suppressed Id3 expression. d–g The cytoplasmic calcium ion concentration was elevated after LIPUS stimulation (n = 3). h, i CaN activity was enhanced after LIPUS stimulation (n = 3). j–p Simultaneous immunofluorescence and nuclear protein Western blot showed that LIPUS induced nuclear translocation of NFATC3 (n = 3) Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (t-test for (e, g, h, i, k, l, n, and p))Fig. 8LIPUS inhibits Id3 expression by activating the Ca²⁺/CaN/NFATC3 signaling pathway. a–d Gsmtx4 reduced LIPUS-induced intracellular calcium concentration but was hardly affected by CsA and VIVIT peptide (n = 3). e, f LIPUS-induced CaN activity was blocked by Gsmtx4 and CsA (independent of VIVIT) (n = 3). g–k LIPUS-induced nuclear translocation of NFATC3 were blocked by Gsmtx4, CsA, and VIVIT (n = 3). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way ANOVA for b, d, e, f, i, and k) LIPUS inhibit Id3 by target NFATC3. a Pattern Diagram: LIPUS inhibits Id3 expression by activating the Ca²⁺/CaN/NFATC3 signaling pathway (Created with BioRender.com). b RNA-seq pathway enrichment analysis showed that LIPUS intervention significantly activated the pathway related to calcium inward flow. c KnockTF 2.0 database analysis revealed that the transcription factor NFATC3 significantly suppressed Id3 expression. d–g The cytoplasmic calcium ion concentration was elevated after LIPUS stimulation (n = 3). h, i CaN activity was enhanced after LIPUS stimulation (n = 3). j–p Simultaneous immunofluorescence and nuclear protein Western blot showed that LIPUS induced nuclear translocation of NFATC3 (n = 3) Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (t-test for (e, g, h, i, k, l, n, and p)) LIPUS inhibits Id3 expression by activating the Ca²⁺/CaN/NFATC3 signaling pathway. a–d Gsmtx4 reduced LIPUS-induced intracellular calcium concentration but was hardly affected by CsA and VIVIT peptide (n = 3). e, f LIPUS-induced CaN activity was blocked by Gsmtx4 and CsA (independent of VIVIT) (n = 3). g–k LIPUS-induced nuclear translocation of NFATC3 were blocked by Gsmtx4, CsA, and VIVIT (n = 3). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way ANOVA for b, d, e, f, i, and k) Id3 inhibitory peptide (rID3) enhances LIPUS-induced osteogenesis After discovering the braking mechanism of Id3, we designed rID3 to disrupt the Id3-E2A interaction. rID3 can prevent the binding of Id3 to E2A, thereby relieving the inhibition of E2A (Supplementary Fig. 12a). Subsequently, we validated its functionality. First, we performed a preliminary cytotoxicity assessment using a series of peptide concentration gradients and determined 1 μmol/L as the in vitro intervention concentration (Supplementary Fig. 12b, c). Our data show that rID3 can successfully penetrate the membrane and enter the nucleus in both mBMSCs and hBMSCs. At the cellular level, ARS and ALP staining experiments confirmed that rID3 synergistically enhances the osteogenic tendency of BMSCs induced by LIPUS (Fig. 9a–d, Supplementary Fig. 12d–g). Following this, we established a mouse cranial defect model and further investigated the sensitizing effect of rID3 on LIPUS through Micro-CT, H&E staining, and Masson trichrome staining (Supplementary Fig. 12h). The results demonstrated that, at 8 weeks post-surgery, the skull defect (2 mm non‑critical / 4 mm critical) repair rate in the LIPUS combined with rID3 treatment group was significantly higher than that in the LIPUS group and the rID3 group. H&E and Masson staining also indicated a significant increase in new bone formation in the combined treatment group (Fig. 9e–g, Supplementary Fig. 12i), demonstrating highly efficient repair effects. Compared with other groups, the combination therapy group showed a significant increase in BV/TV, Tb. Th, Tb. N, and a significant decrease in BS/BV and Tb. pf (Fig. 9h–l). Importantly, fluorescence imaging of major organs (Supplementary Fig. 9) and H&E staining (Supplementary Fig. 13) further confirmed the good biosafety of rID3 Fig. 10.Fig. 9rID3 enhances LIPUS-induced osteogenesis. a rID3 can successfully penetrate the membrane and enter the nucleus in mBMSCs (n = 3). b-d ARS and ALP staining experiments confirmed that rID3 synergistically enhances the osteogenic tendency of mBMSCs induced by LIPUS (n = 3). e Representative CT images, H&E and Masson images of skull defects in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups after 8 weeks of modeling (n = 5). f Body weight of mice in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups after 8 weeks of modeling (n = 5). g Quantification of skull defects in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups after 8 weeks of modeling (n = 5). h–l Quantitative analysis: femoral BV/TV, Tb. Th, Tb. N, BS/BV, Tb. pf in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups (n = 5). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way ANOVA for c, d, and f–l)Fig. 10Schematic illustrating the CaN/NFATC3/Id3/E2A/Bmp4 signaling pathway through which LIPUS mechanotransduction promotes bone regeneration, and the synergistic effect of the rID3 targeting the Id3/E2A interface to enhance cranial bone defect healing rID3 enhances LIPUS-induced osteogenesis. a rID3 can successfully penetrate the membrane and enter the nucleus in mBMSCs (n = 3). b-d ARS and ALP staining experiments confirmed that rID3 synergistically enhances the osteogenic tendency of mBMSCs induced by LIPUS (n = 3). e Representative CT images, H&E and Masson images of skull defects in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups after 8 weeks of modeling (n = 5). f Body weight of mice in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups after 8 weeks of modeling (n = 5). g Quantification of skull defects in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups after 8 weeks of modeling (n = 5). h–l Quantitative analysis: femoral BV/TV, Tb. Th, Tb. N, BS/BV, Tb. pf in FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS groups (n = 5). Values are means ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000 1; ns, no significance. (one-way ANOVA for c, d, and f–l) Schematic illustrating the CaN/NFATC3/Id3/E2A/Bmp4 signaling pathway through which LIPUS mechanotransduction promotes bone regeneration, and the synergistic effect of the rID3 targeting the Id3/E2A interface to enhance cranial bone defect healing Discussion Sonogenetics is an emerging interdisciplinary field dedicated to understanding how ultrasound can be utilized to precisely control gene expression and intracellular signaling networks, thereby achieving targeted programming and manipulation of cellular functions.10 Conventional mechanisms of ultrasound action depend on its mechanical, thermal, and chemical effects, such as acoustic streaming, cavitation, radiation force, and absorptive heating.8,31 These effects can directly induce changes in cellular behaviors, including anti-inflammatory responses,32 cytoskeletal reorganization,33 neural pathway activation,34 angiogenesis,35 and osteogenic differentiation of mesenchymal stem cells.36 However, from a sonogenetics perspective, it is further revealed that these mechanical effects may activate mechanosensitive ion channels like Piezo1, induce calcium influx, and trigger downstream signaling events such as ERK1/2 phosphorylation and perinuclear F-actin polymerization.12 These processes subsequently promote COX-2 expression through pathways involving FAK, ERK, PI3K, and Wnt, ultimately enhancing bone formation.37 Despite these advances, the transcriptional cascade logic by which mechanical signals are transmitted from membrane channels to the nucleus to precisely regulate gene expression remains poorly understood at a systematic level, particularly regarding whether more critical regulatory nodes exist within this process. The present study, through integrated transcriptomic analysis and functional validation, reveals for the first time that the nuclear factor Id3 serves as a key inhibitory hub in response to ultrasound-mediated mechanical stimulation. Our data consistently demonstrate that while LIPUS promotes osteogenic differentiation, it significantly downregulates Id3 expression. Functional assays confirm that Id3 acts as a “molecular brake” by directly suppressing the transcription of Bmp4, a critical osteogenic gene. Consequently, pharmacological inhibition of Id3 effectively relieves this negative feedback mechanism, thereby markedly amplifying the pro-osteogenic effects of LIPUS. This discovery not only deepens our understanding of ultrasound-induced mechanotransduction but also identifies a highly promising molecular target for advancing more precise and efficient ultrasound-based therapeutic strategies. Traditional ultrasound therapy is fundamentally a form of macroscopic physical stimulation. After its energy is absorbed by tissues, it triggers a broad range of biological effects.38 However, this mode of stimulation lacks cellular selectivity, which constitutes a major reason for the considerable individual variability in its clinical efficacy and its suboptimal outcomes in some patients with deep bone defects.15 Recent breakthroughs in the field of sonogenetics have provided a novel perspective. This technology enables non-invasive and precise modulation of specific cell populations using ultrasound by genetically engineering target cells to express ultrasound-responsive molecules.39 The key factor, Id3, identified in our study, serves as a critical bridge toward achieving this translational advancement. Id3, one of the IDs, is a helix-loop-helix (HLH) transcription factor that lacks the essential region required for DNA binding found in other HLH proteins.40 Id3 binds to basic HLH proteins (such as E protein) and disrupts the formation of dimers, thus inhibiting DNA binding and transcriptional activity. As key regulators of E proteins, Id3 proteins have been implicated in a critically important role in BMSCs, macrophages, T cells, and B cells.41,42 Our data showed Id3 as the key factor between ultrasound and cellular activity, which provides an integrated ultrasound-regulating gene circuit for ultrasound therapy. Evidence has shown that Id3 plays a crucial role in stem cell proliferation and self-renewal.43,44 Id3 determines cellular responses to TGFβ and BMP signaling pathways. Id3 expression has been reported to be down-regulated in TGFβ and upregulated by BMPs,45 and Id3 has been shown to promote cell proliferation accompanied by inhibition of osteogenic differentiation,46,47 indicating the reverse functions of Id3 in regulating cell proliferation and osteogenesis. Our previous study reported that BMP4 was similarly significantly upregulated after Id3 deletion, and Id3 negatively regulated BMP4 and prostaglandin E2 (PGE2) expression by preventing the binding of basic HLH protein E2A in BMSCs.22 This is consistent with previous studies, as BMP4 and PGE2 have been found to function in ultrasound stimulation for bone healing.48 To explore the mechanism of ultrasound and Id3 in bone formation, our in vivo and in vitro experiments showed that ultrasound enhanced Bmp4-p-Smad1/5-Runx2 signal transduction in bone by down-regulating Id3. All these data indicate that there is negative feedback between Id3 and BMP4. Thus, downregulating Id3 would enhance BMP4-induced bone formation. Furthermore, we discovered that ultrasound activates CaN/NFATC3 to negatively regulate Id3 in an intracellular calcium-dependent manner, which clarifies the core signaling node connecting ultrasound stimulation to Id3. The elucidation of this sonogenetic pathway not only provides a molecular basis for understanding ultrasound-induced biological effects, but also establishes a theoretical foundation for developing programmable and highly targeted gene regulation strategies mediated by ultrasound. Although many clinical trials show positive effects of ultrasound therapy, a few studies reported that ultrasound does not affect functional recovery.49 Furthermore, it was reported that ultrasound therapy treatment failed to treat deep bone healing.50 We believe this is due to inhomogeneous and insufficient targeting of ultrasound therapy. In our study, we identified for the first time a transcriptional repressor of ultrasound therapy, Id3, which blocks ultrasound-induced bone formation and provides a target for designing ultrasound sensitization means. Based on this pivotal discovery, we innovatively designed and developed an inhibitory peptide targeting the function of Id3. This peptide mimics the key binding domain of Id3 with its interacting protein E2A, enabling it to competitively disrupt the Id3-E2A interaction. Consequently, this intervention effectively releases the suppression of osteogenic signaling exerted by Id3. In a murine calvarial critical-sized defect model, the combined strategy of LIPUS and the Id3 inhibitory peptide demonstrated a significant synergistic effect. This outcome was markedly superior to results obtained with LIPUS alone or in control groups. These results powerfully demonstrate that targeted intervention against Id3 is an effective strategy for overcoming the inherent therapeutic limitations of LIPUS and substantially enhancing its efficacy in bone repair. From a clinical translation perspective, this strategy holds significant potential for addressing challenging issues in orthopedics, such as non-union of osteoporotic fractures, large bone defects, and post-radiation osteonecrosis. These conditions are characterized by a compromised local biological environment and severely impaired endogenous osteogenic capacity, often rendering conventional LIPUS stimulation insufficient. Our approach aims to fundamentally enhance the responsiveness of target cells to physical stimulation, thereby converting a “weak response” into a “strong response”. Compared with systemic drug administration, the combination of localized pharmacological intervention and non-invasive physical therapy offers dual advantages of high targeting precision and low side effects. Nonetheless, translating this strategy into clinical practice requires extensive further work, including validation of efficacy in large animal models, optimization of delivery efficiency and safety, and the development of non-invasive gene regulation technologies. Moreover, translating this discovery into clinical application necessitates addressing the challenges posed by the intrinsic biological properties of the Id3 protein itself. Id3 (and its Id protein family) is a prototypical short-lived protein exhibiting extremely low stability. It is primarily degraded rapidly via the ubiquitin-proteasome pathway (UPS), typically maintaining an exceedingly short half-life of only 10-20 minutes post-synthesis. Critically, Id3 expression levels are not static but are dynamically regulated by diverse intrinsic and extrinsic factors, including cell type, cell cycle stage, and differentiation status.40,51 This highly dynamic and cell-state/individual-dependent expression pattern implies that baseline Id3 levels and LIPUS-induced Id3 expression may exhibit substantial variations among different patients or even within the same patient’s lesion tissue at different time points.52 Therefore, the expression status of Id3 is likely a critical variable determining individual responsiveness to LIPUS therapy and constitutes a core factor influencing the therapeutic stability of our designed Id3 inhibitory peptide strategy. Future research needs to focus on (1) Elucidating the spatiotemporal dynamics of ultrasound-regulated Id3 expression and stability, particularly across different stages of bone repair and under various pathological conditions; (2) Optimizing the delivery strategy for the Id3 inhibitory peptide (e.g., developing sustained-release carriers) to overcome its rapid degradation in vivo; (3) Expanding the panoramic landscape of the sonogenetic regulatory network to enable parallel manipulation of multiple genetic circuits, thereby advancing ultrasound therapy from empirical applications toward programmable and individualized gene-level interventions. This study has several limitations. As a widely expressed transcription factor, Id3 plays critical roles in multiple tissues and organs beyond bone, and potential systemic or indirect effects of Id3 modulation were not fully evaluated. Although the Id3 inhibitory peptide rID3 was locally administered, it lacks strict bone tissue targeting, and potential influences on the local microenvironment cannot be completely ruled out. Meanwhile, as a physical stimulus, LIPUS may exert potential effects on surrounding tissues such as vascular endothelial and neural cells, which warrants further investigation. In summary, we demonstrate that Id3 acts as a transcriptional repressor of ultrasound stimulation during bone formation. This repression is both necessary and sufficient to enhance the osteogenesis of BMSCs and holds therapeutic potential for bone formation. Our results identify Id3 as a key factor linking ultrasound, cellular activity, and osteogenesis, thereby providing an integrated ultrasound-regulated gene circuit for ultrasound therapy or ultrasound-assisted strategies. Furthermore, we elucidate the “braking mechanism” by which Id3 limits mechanically loading-induced osteogenesis through the inhibition of Bmp4-Smad1/5-Runx2 cascade activation. Targeting this mechanism, we have developed and designed an inhibitory peptide against Id3. This innovative strategy not only addresses the current limitations of ultrasound therapy but also establishes a novel combinatorial approach for precision sonogenetics, offering enhanced therapeutic potential for bone regeneration. Methods And Materials Cell culture and Intervention hBMSCs and mBMSCs were purchased from Cyagen (Guangzhou, China; HUXMA-01001, MUBMX-01001). Cells were cultured in specific medium (Cyagen; HUXMA-90011, MUXMX-90011). For LIPUS, BMSCs were seeded in plates. For drug treatment, cells were exposed for 24 hours to: DMH-1 (10 μmol/L, HY-12273, MCE), Gsmtx4 (40 μmol/L, HY-P1410, MCE), NFAT inhibitor-1 VIVIT (10 μmol/L, HY-P1026, MCE), or Cyclosporin A (1 mol/L, HY-B0579, MCE). To study Id3's role, BMSCs were isolated from 4-week-old male Id3 KO and WT mice. Mice were euthanized, disinfected, and femurs/tibiae dissected. Bone ends were cut, and marrow cavities flushed with medium. The flush was centrifuged (1 100 r/min, 5 min). Cells were plated. After 48–72 hours, non‑adherent cells were removed. At 80–90% confluence, cells were passaged to P3. Stem cell markers (Sca-1, CD105, CD11b, CD45) were verified by flow cytometry. Cells were maintained at 37°C, 5% CO₂ and used for experiments. Animal model All animal experiments were approved by the Animal Care and Ethics Committee of Capital Medical University (AEEI-2022-271). Male mice (C57BL/6, 4–6 weeks old, Beijing SPF Biotechnology; Id3 KO, 4–6 weeks old, Cyagen) were housed under specific pathogen‑free conditions with free access to food and water. Femurs from 12‑month‑old Id3 KO and WT mice were collected for micro‑CT analysis. LIPUS screening trial: 8‑week‑old C57BL/6 mice were randomized into control and LIPUS groups (n = 4 per group). The right hind limb received LIPUS stimulation; the left served as control. Validation trial: 8‑week‑old C57BL/6 mice were randomized into four groups (n = 5 per group): Control, AAV9‑NC, AAV9‑NC+LIPUS, and AAV9‑Id3+LIPUS. LIPUS was applied to the right hind limb. Calvarial defect experiment: 6‑week‑old C57BL/6 mice were randomized into four groups (n = 5 per group): FBS, FBS+LIPUS, Peptide, and Peptide+LIPUS. After one week of acclimation, a 2 mm or 4 mm circular calvarial defect was created under sterile conditions using a trephine drill with saline cooling. The wound was sutured, and interventions began one week later. LIPUS LIPUS signal is managed by an OSTEOTRON IV ultrasonic device (ITO Ultrashort Wave Co., Ltd., Tokyo, Japan). The parameters are set as follows: intensity of 30 mW/cm2, frequency of 1 MHz, pulse width of 200 μs, and duty cycle of 20%. During the experiment, the transducer probe is coated with a gel coupling agent close to the bottom of the cell orifice plate or the skin of the mouse’s hind limbs or calvaria. The stimulation time was 30 minutes, five days a week. Plasmid construction and infection All relevant plasmids were purchased from Shanghai Gene Chem Co., Ltd. Lipofectamine 3000 transfection reagent (Invitrogen, L3000015) improves transfection efficiency. The specific steps are as follows: (1) inoculate cells to make them reach 70%-90% confluence during transfection; (2) using Opti-MEM™ (Invitrogen, 31985062) culture medium to dilute Lipofectamine™ 3000 reagent, and thoroughly mixing; (3) diluting DNA with Opti-MEM™ culture medium to prepare DNA premix, then adding P3000™ reagent and thoroughly mixing; (4) uniformly mixing the solutions in the above two steps and incubating for 10-15 minutes; (5) replacing the antibiotic-free cell culture medium, adding the mixed solution into the cell culture medium, and gently shaking the culture medium to make it uniform; (6) incubate the cells at 37 °C for 2 days, and carry out subsequent experiments. RT-qPCR determined transfection efficiency. Construction and application of AAV rAAV9.DSS-Nter-Id3 (overexpressing Id3) and rAAV9.DSS-shId3 (knocking down Id3) are two bone-targeting recombinant adeno-associated viruses (rAAV) constructed by Shanghai GeneChem Co., Ltd. The product number for the overexpression virus is GOSV0393532, and for the knockdown virus is GOSV5047473. Both viruses target the mouse Id3 gene (reference sequence NM_008321.2), and their capsids consist of an AAV9 backbone fused with the DSS bone-targeting peptide (not an independent serotype). The vector ID for the overexpression virus is GV812, and its element sequence is: CMV-betaGlobin-EGFP-T2A-MCS-3Flag-WPRE-bGH poly(A); the element sequence for the knockdown virus is: CMV promoter-EGFP-MIR155(MCS)-WPRE-SV40 PolyA. The two viruses are administered separately via tail vein injection into mice, with a single injection dose of 5 × 1011 viral genomes (vg) per mouse (dissolved in 100 μL volume). The virus takes effect within two weeks, and peak expression is reached at four weeks. Osteogenic differentiation and detection Osteogenic differentiation of BMSCs was induced by the MSC Osteogenic Differentiation Kit (Cyagen Biosciences, HUXMX-90021, and MUXMX-90021), and the culture medium was changed every three days. On the 7th day of induction, cells were stained with an ALP chromogenic kit (Beyotime, C3250S), and an ALP detection kit (Beyotime, P0321S) was used to evaluate the osteogenic ability of cells. On the 21st day of induction, calcium nodules were stained with ARS (Cyagen Biosciences, ALIR-10001) to assess the degree of mineralization. After taking photos and recording, the dye was eluted with 10% cetylpyridinium chloride for 30 min, and the optical density (OD) was measured at 562 nm. Cell activity detection Cells were inoculated in a confocal culture dish (Cellvis, D35C4-20-1-N). After the intervention, the cells’ proliferation rate was measured using a Ki67 detection kit (Beyotime, C2301S) and an EdU detection kit (RiBoBio, C10310-1). TUNEL assay kit (RiBoBio, C11026-2) was used to determine the apoptosis rate. Flow cytometry Single-cell suspension was prepared by conventional digestion of cells, and the cell concentration was diluted to about 1 × 106 cells per 100 μL. Subsequently, appropriate antibodies were added according to the standard instructions (Sca-1, Biolegend, 108127; CD105, Biolegend, 120413; CD45, Biolegend, 157607; CD11b, Biolegend, 101207), gently mixed and incubated in the dark at 4°C. After washing with precooled PBS twice, cells were rapidly analyzed using LSRFortessa (from BD Biosciences) to determine the proportion of cells labeled with various fluorescent markers in each channel. The data were analyzed by using FlowJo software. Micro-CT The structure of the femur and tibia in mice was analyzed with a high-resolution Inveon CT/PET/SPECT scanner (Siemens, Germany). A three-dimensional bone structure image was reconstructed using a CT-Analyser, CT-Volume, and CT-Voxel (Skyscan, Belgium). The following parameters were analyzed: BV/TV, Tb. Th, Tb. N, BMD, BS/BV, SMI and Tb. pf. Double labeling of calcein/xylenol orange Calcein (Sigma, C0875) was injected intraperitoneally before LIPUS intervention, and xylenol orange (Sigma, 52097) was injected intraperitoneally four days before euthanasia in mice. The dosage of the two reagents was 30 mg/kg. After euthanasia, the tibia was taken for histological analysis, and the tibia section was observed by confocal microscope. The distance between two fluorescent lines was the amount of bone formation between the two injections. Western blot Total cellular protein was extracted from cells by RIPA lysis and extraction buffer (Beyotime, P0013B), while nuclear protein was extracted strictly according to the instructions using a professional reagent kit (Beyotime, P0028). The BCA method determined the protein concentration (Beyotime, P0011). SDS-PAGE separated an equal amount of protein, transferred to the PVDF membrane (Sigma-Aldrich, IPVH00010), and then blocked with a quick blocking solution (Beyotime, P0252). Primary antibody (Bmp4, Abcam, ab155033, 1: 1 000 dilution; p-Smad1/5, CST, 13820 T, 1:1 000 dilution; Runx2, Abcam, ab192256, 1:1 000 dilution; Osx, Abcam, ab209484, 1:1 000 dilution; NFATC3, Proteintech, 18222-1-AP, 1:1 000 dilution; Lamin B1, Proteintech, 12987-1-AP, 1:1 000 dilution; and GAPDH, Abclonal, A19056, 1: 1 000 dilution) was incubated overnight at 4°C, and then the secondary antibody (GOAT anti-rabbit IgG H&L, ABCAM, AB6721, 1: 5 000 dilution) was incubated at room temperature for 1 hour. ECL Chemiluminescence Kit (Beyotime, P0018M) was used for exposure and development. Finally, the protein bands were semi-quantitatively analyzed by ImageJ and normalized by internal reference. Immunofluorescence Mouse tibia tissue was collected, fixed, and decalcified. Paraffin specimens were prepared and sliced into 5-μm-thick sections. After baking the slices at 60°C overnight, the slices were deparaffinized with xylene and hydrated in gradient ethanol. Antigen repair (heat repair) was performed and then naturally cooled to room temperature. Normal goat serum-blocking solution was applied at room temperature for one hour. Primary antibodies were incubated overnight at 4 °C (Bmp4, Abcam, ab155033, 1:500 dilution; p-Smad1/5, CST, 13820 T, 1:500 dilution; Runx2, Abcam, ab192256, 1:500 dilution; Osx, Abcam, ab209484, 1:500 dilution; and NFATC3, Proteintech, 18222-1-AP, 1:500 dilution). Fluorescent secondary antibody (Alexa Fluor™ 647, ThermoFisher, A-31573, 1:1 000 dilution) was incubated at room temperature and protected from light for one hour before DAPI staining and sealing. Tissue images were acquired under confocal. ChIP assay According to the manufacturer’s instructions, the ChIP assay was performed using a Pierce Magnetic ChIP Kit (Thermo Scientific™, 26157). The cells were fixed with 1% formaldehyde at room temperature for 10 minutes to crosslink protein with DNA, and then the reaction was stopped with glycine. Next, cell components were dissolved in lysis buffer, chromatin was fragmented by ultrasonic treatment of lysate, and the fragments were incubated with anti-E2A antibody (Proteintech, 21242-1-AP) and control IgG. These complexes were captured by Protein A/G magnetic beads, magnetically separated by a magnetic frame, and then washed to remove nonspecific substances. The crosslinking was reversed by heating, and the DNA was released from the protein complex. Finally, the DNA was purified by using a DNA purification centrifuge column. The DNA of chromatin immunoprecipitation was analyzed by qPCR using the following primers: (1) Validation of E2A and BMP4 binding sites: Mouse, Forward 5’-AGGCCACCTTTAAACCAAT-3’, Reverse 5’-AATCACCATTTACCCCGAGT-3’; Human, Forward 5’-TGTGTTCCACAGGAAGTAGTTC-3’, Reverse 5’-TCCCTGGACAGACATGACAC-3’. (2) Validation of NFATC3 and Id3 binding sites: Mouse, Forward 5’-ACCGAAATAGCTGTCCTTGAGA-3’, Reverse 5’-CCAGTCTCGGAGCCTCATTC-3’; Human, Forward 5’-ACTGAAGAGCCTGTCCTTGA-3’, Reverse 5’-AGCAGAGCCAGTCTTGAAGC-3’. RNA-seq and PCR array RNA‑seq analysis was completed using the Illumina NovaSeq 6000 platform provided by Novogene (China, Tianjin), and the data was analyzed according to the manufacturer’s standard scheme. Customized Wcgene Biotech (Shanghai, China) detected the expression of 44 inhibitory transcription factors. Mouse PCR Array analysis was conducted following the manufacturer’s protocol (Wcgene Biotech, Shanghai, China), and data were analyzed using Wcgene Biotech software. RT-qPCR According to the manufacturer’s experimental scheme, RNAprep Pure kit (TIANGEN, DP430, DP431) was used to purify high-quality total RNA from cells and bone tissues. FastKing cDNA first-strand synthesis kit (TIANGEN, KR116-02) was used for reverse transcription. The target gene was amplified in the CFX96 Touch real-time fluorescence quantitative PCR detection system (Bio-Rad Laboratories, USA) using NovoStart SYBR qPCR SuperMix Plus (Novoprotein, E096-01b). The reference genes were normalized and statistically analyzed. Primer sequences are shown in Supplementary Table 1. CaN activity assay Cell samples from groups were processed according to the designated conditions, and protein extraction and concentration determination were performed following the Western blot protocol. Calcineurin concentration was measured using a commercial assay kit (Nanjing Jiancheng, A068-1-1) strictly according to the manufacturer’s instructions. Calcium ion fluorescence probe detection The intracellular calcium concentration was measured using a professional assay kit (Beyotime, S1060). Briefly, an appropriate amount of Fluo-4 AM stock solution was diluted with PBS to prepare a 1 μmol/L working solution. For cultured cells to be tested, the culture medium was removed, and the cells were washed three times with PBS or HBSS buffer. The Fluo-4 AM working solution was then added in sufficient volume to completely cover the cell monolayer. Cells were incubated at 37°C for 20 minutes to allow fluorescent probe loading. After incubation, cells were washed three times with PBS and further incubated for 20 minutes to ensure complete intracellular conversion of Fluo-4 AM to its active form, Fluo-4. Following 20 minutes of LIPUS (low-intensity pulsed ultrasound) stimulation, Fluo-4 fluorescence was detected using a confocal laser scanning microscope to determine changes in intracellular calcium ion concentration. rID3 construction, validation, and functional testing The rID3 peptide (sequence: FITC-YGRKKRRQRRR-GGGS-TQLSQV-GGGS-PKKKRKV), designed according to our previously granted Chinese patent (ZL201910680615.6), was synthesized by Nanjing Jetide Biotech Co. For validation experiments, 10 000 cells were seeded per well in confocal dishes. After adhesion, cells were treated with 1 μmol/L rID3 for 48 hours, followed by fixation for 20 min. Cells were then washed twice with PBS and 2–4 times with PBS containing 0.1% Triton X-100 (5 min each). For fluorescence staining, Actin-Tracker Red (Beyotime, C2205S) was diluted 1:100 in immunofluorescence secondary antibody dilution buffer, and 200 µL was added per well, followed by 30 min incubation at room temperature in the dark. After three PBS washes (5 min each), nuclei were stained with DAPI for 5 min and washed again with PBS three times (5 min each). The cellular uptake and nuclear localization efficiency of rID3 were then assessed by confocal microscopy. For functional testing in vivo, the calvarial defect model was treated with local injections of rID3 (1 mg/kg in 50 µL) administered 5 days per week, combined with daily LIPUS stimulation (5 daysperweek), and samples were collected after 2 months. For in vitro osteogenic induction experiments, the standard protocol was followed with the addition of 1 μmol/L rID3 each time the osteogenic induction medium was refreshed. Histological section TRAP staining After routine deparaffinization and rehydration, paraffin sections were treated with pre-chilled TRAP fixative for 1 minute. The fixative was then discarded, and the sections were rinsed with distilled water. Next, TRAP incubation solution (Sigma-Aldrich, MO, USA) was applied, and the sections were incubated at 37 °C for 1 hour. Following another rinse with distilled water, the nuclei were stained with hematoxylin for 2 minutes, followed by bluing in running tap water for 10 minutes. Finally, after a final wash with distilled water, the sections were mounted using an aqueous mounting medium. H&E and Masson staining The collected calvarial samples were fixed in 4% paraformaldehyde for 24 hours, decalcified in 10% EDTA for about 2 weeks (with regular solution changes until softening), dehydrated through graded alcohols, embedded in paraffin, and sectioned at 5 μm. For H&E staining, sections were dewaxed, rehydrated, stained with hematoxylin for 5 minutes, differentiated in acid alcohol, counterstained with eosin for 2 minutes, dehydrated, cleared, and mounted with neutral resin. For Masson staining, sections were similarly dewaxed and rehydrated, stained with Weigert’s iron hematoxylin (5 min) and Ponceau-acid fuchsin (5 min), treated with phosphomolybdic acid, stained with aniline blue (5 min), then dehydrated, cleared, and mounted. Staining times were adjusted based on microscopic evaluation. Sections were observed and imaged under a light microscope. H&E staining assessed bone morphology, and Masson staining analyzed collagen distribution. Bibliometric analysis This study conducted a literature search on March 20, 2024, using the Science Citation Index Expanded (SCI-E) database within the Web of Science (WOS), which is commonly used in bibliometric studies.8,53 To ensure the accuracy and comprehensiveness of the search results, the search terms and search strategies were designed and optimized in this study (Supplementary Table 2). Search results were exported in plain text file format. The exported data were further analyzed using the bibliometric tool Citespace (Version 6.2 R4). Keywords can succinctly summarize the topic and content of an article, and the analysis and study of keywords in a field of literature can analyze the research hotspots and emerging trends in the field.54 Citespace will be used to perform co-occurrence analysis and burst detection analysis of keywords. Citespace will be used to recognize the current state of research in the Id3 and bone research field. Statistical analysis The statistical data were obtained from at least three independent experiments and expressed as mean ± SD. The analysis and visualization of the data were conducted using GraphPad Prism version 10.1.2. To assess differences between the two groups, Student’s t-test was employed, while ANOVA was utilized for comparisons involving three or more groups. A p-value of less than 0.05 was deemed statistically significant, with significance levels indicated as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.000 1. Supplementary information Supplementary Figs. 1–13, Supplementary Tables 1, 2. Supplementary Figs. 1–13, Supplementary Tables 1, 2.